Ovarian reserve diminished by oral cyclophosphamide therapy for granulomatosis with polyangiitis (Wegener's)

Arthritis Care and Research

Volumn 63, Issue 12, 2011, Pages 1777-1781

  Clowse, Megan E B ^a   Copland, Susannah C ^a   Hsieh, Tsung Cheng ^a   Chow, Shein Chung ^a   Hoffman, Gary S ^b   Merkel, Peter A ^c   Spiera, Robert F ^d   Davis Jr , John C ^e   McCune, W Joseph ^f   Ytterberg, Steven R ^g   St Clair, E William ^a   Allen, Nancy B ^a   Specks, Ulrich ^g   Stone, John H ^h  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c BOSTON UNIVERSITY   (United States)

^d HOSPITAL FOR SPECIAL SURGERY   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF MICHIGAN   (United States)

^g MAYO CLINIC   (United States)

^h MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; ETANERCEPT; FOLLITROPIN; GLUCOCORTICOID; METHOTREXATE; MUELLERIAN INHIBITING FACTOR; PLACEBO; PREDNISONE; BIOLOGICAL MARKER; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR;

ADOLESCENT; ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EXPOSURE; FEMALE; FOLLITROPIN BLOOD LEVEL; HORMONE BLOOD LEVEL; HUMAN; KIDNEY DYSFUNCTION; MENOPAUSE; OOCYTE TRANSPORT; OVARIAN RESERVE; PREGNANCY; RANDOMIZED CONTROLLED TRIAL; WEGENER GRANULOMATOSIS; BLOOD; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; OVARY; PATHOPHYSIOLOGY; PREMATURE OVARIAN FAILURE; TIME; TREATMENT OUTCOME; UNITED STATES;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTI-MULLERIAN HORMONE; BIOLOGICAL MARKERS; CYCLOPHOSPHAMIDE; DOUBLE-BLIND METHOD; FEMALE; FOLLICLE STIMULATING HORMONE, HUMAN; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; METHOTREXATE; MIDDLE AGED; OVARY; PRIMARY OVARIAN INSUFFICIENCY; RECEPTORS, TUMOR NECROSIS FACTOR; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; WEGENER GRANULOMATOSIS; YOUNG ADULT;

EID: 84855983679     PISSN: 21514658     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/acr.20605     Document Type: Article

References (14)

1. Park MC, Park YB, Jung SY, Chung IH, Choi KH, Lee SK. Risk of ovarian failure and pregnancy outcome in patients with lupus nephritis treated with intravenous cyclophosphamide pulse therapy. Lupus 2004;13:569-74. (Pubitemid 39145485)
2. Huong DL, Amoura Z, Duhaut P, Sbai A, Costedoat N, Wechsler B, et al. Risk of ovarian failure and fertility after intravenous cyclophosphamide: a study in 84 patients. J Rheumatol 2002;29:2571-6. (Pubitemid 35416964)
3. Te Velde ER, Pearson PL. The variability of female reproductive ageing. Hum Reprod Update 2002;8:141-54. (Pubitemid 34428965)
4. Visser JA, de Jong FH, Laven JS, Themmen AP. Anti-Mulle-rian hormone: a new marker for ovarian function. Reproduction 2006;131:1-9. (Pubitemid 43230697)
5. Fanchin R, Taieb J, Lozano DH, Ducot B, Frydman R, Bouyer J. High reproducibility of serum anti-Mullerian hormone measurements suggests a multi-staged follicular secretion and strengthens its role in the assessment of ovarian follicular status. Hum Reprod 2005;20:923-7. (Pubitemid 40667836)
6. Van Rooij IA, Broekmans FJ, Scheffer GJ, Looman CW, Habbema JD, de Jong FH, et al. Serum antimullerian hormone levels best reflect the reproductive decline with age in normal women with proven fertility: a longitudinal study. Fertil Steril 2005;83:979-87.
7. Nelson SM, Messow MC, Wallace AM, Fleming R, McConnachie A. Nomogram for the decline in serum antimullerian hormone: a population study of 9,601 infertility patients. Fertil Steril 2011;95:736-41.
8. Sowers MR, Eyvazzadeh AD, McConnell D, Yosef M, Jan-nausch ML, Zhang D, et al. Anti-mullerian hormone and inhibin B in the definition of ovarian aging and the menopause transition. J Clin Endocrinol Metab 2008;93:3478-83.
9. Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's gran-ulomatosis. N Engl J Med 2005;352:351-61.
10. Lie Fong S, Lugtenburg PJ, Schipper I, Themmen AP, de Jong FH, Sonneveld P, et al. Anti-mullerian hormone as a marker of ovarian function in women after chemotherapy and radiotherapy for haematological malignancies. Hum Reprod 2008; 23:674-8. (Pubitemid 351651205)
11. Blumenfeld Z, von Wolff M. GnRH-analogues and oral contraceptives for fertility preservation in women during chemotherapy. Hum Reprod Update 2008;14:543-52.
12. Clowse ME, Behera MA, Anders CK, Copland S, Coffman CJ, Leppert PC, et al. Ovarian preservation by GnRH agonists during chemotherapy: a meta-analysis. J Womens Health 2009;18:311-9.
13. De Groot K, Harper L, Jayne DR, Flores Suarez LF, Gregorini G, Gross WL, et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med 2009;150:670-80.
14. Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010;363:221-32.